Recently, Pantelidou et al. revealed that interaction of PARP inhibition and STING/TBK1/IRF3 pathway activation regulates T cell recruitment and anti-tumor efficacy in cancer cells (Pantelidou et al., 2019). This evidence concerns the gene IRF3 and neoplasm.